参松养心胶囊联合螺内酯治疗慢性心力衰竭的效果观察

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical value of Shensong Yangxin Capsules combined with Spironolactone in the treatment of chronic heart failure.MethodsA total of 80 patientswith chronic heart failure who had received treatment in our hospital from January 2016 to September 2017 were selected as subjects,and randomly divided into two groups by random number tablemethod,with 40 cases in each group.The control group was treated with Spironolacton,and the observation group was treated with Spironolactone combined with Shensong Yangxin Capsules.The electrocardiogram indexs,heart rate variability indexs,the levels of C-reactive protein(CRP)and serum N-terminal pro-B-type natriuretic peptide(NT-proBNP)were compared between the two groups.ResultsAfter treatment,electrocardiography(ECG)indexes(QTD,QRSwave,QTcd)in the observation group were lower than those in the control group,and the differenceswere statistically significant(P＜0.05),but the heart rate variability indexes(PNN50,rMSSD,SDANN,SDNN)in the observation group were higher than those in the control group,the differenceswere statistically significant(P＜0.05).After treatment,the levels of CRP and NT-proBNP in the observation group were respectively(5.09±1.16)mg/L and(567.52±96.33)pg/ml,which were both lower than those in the control group　([6.29±1.27]mg/L,[716.25±132.64]pg/ml),the differences were statistically significant(P＜0.05).The LVEF in the observation group was(59.29±5.16)%,which was higher than that in the control group of(53.02±6.21)%,and the difference was statistically significant(P＜0.05).ConclusionFor patients with chronic heart failure,the combined therapy of Shensong Yangxin Capsules combined with Spironolactone can effectively improve the indexes of ECG and heart rate variability,and reduce the levels of CRP and NT-proBNP.

Key words： Chronic heart failure Shensong Yangxin Capsules Spironolactone Clinical value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Yong-yi
	FENG Li

Cite this article:

HU Yong-yi,FENG Li. Effect of Shensong Yangxin Capsules combined w ith Spironolactone in the treatment of chronic heart failure[J]. 中国当代医药, 2018, 25(16): 157-160.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I16/157

[1]	曾广伟，秦超师，康晓军，等.贝那普利联合螺内酯治疗慢性心力衰竭的疗效观察[J].陕西医学杂志，2017，46（9）：1288-129.
[2]	马妮娜，柴小奇，李子杰，等.参松养心胶囊联合阿托伐他汀对慢性心力衰竭患者心电图相关指标及心率变异性的影响[J].中医学报，2017，32（6）：1025-1028.
[3]	邓斌.银杏叶片联合尼莫地平治疗VCIND的临床研究[J].中国热带医学，2014，14（2）：210-212.
[4]	高子任，隋殿军，李坤.补益强心片对慢性心力衰竭患者心功能和生活质量的影响[J].中国实验方剂学杂志，2013，19（21）：298-301.
[5]	中华医学会心血管病分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[6]	张红新.麝香保心丸治疗冠心病合并慢性心力衰竭伴室性早搏的临床观察[J].中国药房，2015，26（20）：2832-2834.
[7]	田辉，李龙，邓维杰.美托洛尔联合螺内酯治疗慢性心功能不全的疗效及对心功能与血浆NT-proBNP水平的影响[J].中西医结合心脑血管病杂志，2017，15（13）：1605-1608.
[8]	赵军.银杏叶片联合环磷腺苷治疗冠心病慢性心力衰竭临床疗效[J].中医药学报，2015，43（5）：107-109.
[9]	高世龙，彭俊.银杏叶片对不稳定型心绞痛患者血清IL-6、hs-CRP及颈动脉粥样硬化斑块的影响[J].实用预防医学，2014，21（5）：604-606.
[10]	郑设锋，孙维文，黄朝兴，等.螺内酯治疗腹膜透析合并慢性心力衰竭患者的疗效和安全性[J].中国中西医结合肾病杂志，2017，18（4）：329-331.
[11]	陈素琴，黎明江，吴限.贝那普利联合螺内酯治疗慢性心力衰竭疗效和安全性的Meta分析[J].中国心血管病研究，2017，15（8）：739-743.
[12]	周艺，赵新华，王莹，等.曲美他嗪联合参松养心胶囊治疗慢性心衰合并窦性心动过缓的临床疗效[J].心血管康复医学杂志，2016，25（5）：546-549.
[13]	宜海杰，韩秀平，丁国平，等.左西孟旦对急性心衰患者心功能及 cTnT，hs-CRP，NT-proBNP 水平影响[J].现代生物医学进展，2017，17（7）：1314-1317.
[14]	梁森森，陈碧銮，黄旋，等.参麦四逆汤联用贝那普利和螺内酯对慢性心力衰竭患者LVEF及生存结局的影响[J].河南中医，2017，37（5）：797-799.
[15]	徐志远，谢锋，梁惠玲.慢性心力衰竭患者血清NT-proBNP和cTnⅠ联合检测及临床意义分析[J].中国医药科学，2018，8（1）：241-243.
[16]	王浩宇，衣欣，胡奉环.高敏C反应蛋白和血浆N末端原脑钠肽对老年心力衰竭患者预后的影响[J].临床和实验医学杂志，2017，16（1）：63-65.
[17]	朱艾华，郝永，张晓春，等.无创通气对急性左心衰竭患者hs-CRP及NT-proBNP的影响[J].中国当代医药，2016，23（7）：44-47.
[18]	陈绮华.阿托伐他汀联合神经内分泌拮抗剂治疗慢性心力衰竭的临床疗效观察[J].中国医药科学，2016，6（11）：103-105.
[19]	牛嫚嫚，闫奎坡，孙彦琴，等.参松养心胶囊治疗慢性心力衰竭合并室性心律失常的研究进展[J].疑难病杂志，2017，16（7）：732-735.